Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
The field is reaching a point where sleep health will become a top priority for public health as a result of the great strides made in the field over the past year, as well as the effects of the COVID-19 pandemic and lingering care challenges.
Read Full NewsExtended-release buprenorphine injections increase the number of opioid-free days primarily via direct pathways and by suppressing need-related craving, a causal mediation analysis shows.
Moderate-to-severe fatty pancreas is independently linked to a higher risk for incident type 2 diabetes and chronic kidney disease.
1.
Combination Treatment May Improve Multiple Myeloma Outcomes
2.
To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.
3.
Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025
4.
Mortality up for children with leukemia from lowest SES neighborhoods
5.
WHO launches plan for free child cancer medicines
1.
Autophagy: A Double-Edged Sword in Cancer Development, Immune Evasion, and Drug Resistance
2.
Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy
3.
Evidence-Based Pathways for Survivorship Care Planning
4.
Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial
5.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part XIV
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge